1 report

  • Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products

In this trial, ## patients with PASI scores of ##. ## or greater will be randomized ##:##:##:## to receive weekly subcutaneous doses of IMO-## at ##. ##, ##. ##, or ##. ## mg/ kg/ week or placebo for ## weeks.

  • Lymphoma
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • Idera Pharmaceuticals, Inc.